这是FDA与配药房之间围绕tirzepatide短缺问题的最新争议。作为Zepbound和礼来的糖尿病治疗药物Mounjaro的活性成分，tirzepatide的需求激增导致供不应求。

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...

The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to ...

The FDA determined in October that the active ingredient in Mounjaro and Zepbound — tirzepatide — was no longer in shortage after nearly two years. With the drug from Eli Lilly off the ...

Opens in a new tab or window The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA announced Thursday. As a result, compounders will have ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows compounding ...

The stock is gaining in the pre-market hours in response to the encouraging news. Lilly markets tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), as Mounjaro for type II diabetes (T2D ...